Steve Vucic

Featured in: Favicon

nature.com Favicon

bmj.com (+1) Favicon

frontiersin.org Favicon

jamanetwork.com Favicon

tandfonline.com Favicon

thelancet.com Favicon

neurology.org Favicon

annallergy.org Favicon

onlinelibrary.wiley.com

Articles

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

Jun 8, 2023 | thelancet.com | Steve Vucic |William Huynh |Karen Ho

SummaryBackgroundCNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism and reduces oxidative stress. The phase 2, randomised, double-blind, placebo-controlled trial and open label extension RESCUE-ALS trial evaluated the efficacy and safety of CNM-Au8 for treatment of amyotrophic lateral sclerosis (ALS).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →